JHU-083
Based on 9 publication(s) in Google Scholar
JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b+ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.38%
- CAS No.: 1998725-11-3
- Formule: C14H24N4O4
- Masse moléculaire:312.36
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) JHU-083
More- Nature. 2026 Apr;652(8111):1004-1015. [Abstract]
- Cancer Cell. 2020 Sep 14;38(3):334-349.e9. [Abstract]
- Nat Commun. 2024 Feb 16;15(1):1442. [Abstract]
- Metabolism. 2025 Dec 17:176:156469. [Abstract]
- Sci Adv. 2025 Aug 22;11(34):eadw6926. [Abstract]
- Free Radic Biol Med. 2023 Aug 1:204:226-242. [Abstract]
- Front Immunol. 2022 May 19:13:880262. [Abstract]
- Neuropharmacology. 2025 Nov 15:279:110631. [Abstract]
- bioRxiv. 2025 Sep 29:2025.09.28.674326. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
WB
Activité biologique
JHU-083 (1.82 mg/kg, PO) attenuates CSDS-induced increase in glutaminase activity in CD11b+ cells in the prefrontal cortex and hippocampus, but not in the cerebellum. JHU-083 treatment suppresses the CSDS-induced upregulation of IL-1β and TNF-α expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male 7-to 8-week-old C57BL/6J (C57) mice (25-30 g) with chronic social defeat stress (CSDS)[1]
-
Dosage:1.82 mg/kg
-
Administration:PO; every other day for 12 days
-
Result:Ameliorated social avoidance behavior and anhedonia-like behavior induced by CSDS.
Chemical Information
-
CAS No. 1998725-11-3
-
Appearance Solid
-
Masse moléculaire 312.36
-
Formule C14H24N4O4
-
Color Light yellow to yellow
-
SMILES
O=C(OCC)[C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CC(C)C)N)=O
-
Livraison
Shipping with dry ice.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Apr;652(8111):1004-1015. PMID: 41639460
JHU-083 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Apr;652(8111):1004-1015. [Abstract]
Cell numbers (normalized to control) in ZFTA–RELA+, ZFTA–MAML3+ (ST-1) and non-ZFTA fusion cells with or without JHU-083 (0.5, 1 μM) treatment at 96 h.
JHU-083 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Apr;652(8111):1004-1015. [Abstract]
ZFTA–RELA, endogenous RELA and GAPDH in ZFTA–RELA mNSCs (left) and in EP1NS patient-derived cells (right) treated with or without JHU-083 (1, 5 and 10 μM for 96 h).
JHU-083 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Apr;652(8111):1004-1015. [Abstract]
Tumour volume (fold change) in mice with MAF-1329 (ZFTA–RELA+) PDXs treated with vehicle (n = 5), JHU-083 (n = 5, 20 mg kg–1 orally, 2 doses per week), DM-Cit (n = 5, 25 mg kg−1, i.v., 3 doses per week) or a combination of JHU-083 and DM-Cit (n = 5) for 4 weeks.
JHU-083 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Apr;652(8111):1004-1015. [Abstract]
JHU-083 (orally, 20 mg kg–1, 2 doses per week for 5 weeks). Representative bioluminescence images (left) and quantification (right) and haematoxylin and eosin images from spontaneous spinal metastatic tumours in mice with ZFTA–RELA mNSC xenografts treated with vehicle (n = 8), DM-Cit (n = 6) or a combination of JHU-083 and PI-103.
JHU-083 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Apr;652(8111):1004-1015. [Abstract]
Western blots for RELA (relative to GAPDH) depicting changes in ZFTA-RELA fusion protein levels (purple arrow, ~83 kDa) and endogenous RELA (black arrow, 65 kDa) in ZFTA-RELA mNSCs treated with vehicle or JHU-083 (10 µM) alone (left), or in combination with 2mM Itaconate (right) at the indicated concentrations for 96h.
-
Cancer Cell
Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. [Abstract]2020 Sep 14;38(3):334-349.e9. PMID: 32795401 -
Nat Commun
Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus. [Abstract]2024 Feb 16;15(1):1442. PMID: 38365882 -
Metabolism
Liver cancer chronically exposed to palmitate acquires ferroptosis resistance via the downregulation of glutamine-driven hepcidin expression. [Abstract]2025 Dec 17:176:156469. PMID: 41418943 -
Sci Adv
Liver regeneration-associated hepatocellular YAP1 activation prevents colorectal cancer liver metastasis through glutamine competition. [Abstract]2025 Aug 22;11(34):eadw6926. PMID: 40845109 -
Free Radic Biol Med
H1N1 influenza virus infection through NRF2-KEAP1-GCLC pathway induces ferroptosis in nasal mucosal epithelial cells. [Abstract]2023 Aug 1:204:226-242. PMID: 37146698 -
Front Immunol
Targeting Glutamine Metabolism Ameliorates Autoimmune Hepatitis via Inhibiting T Cell Activation and Differentiation. [Abstract]2022 May 19:13:880262. PMID: 35663990
JHU-083 purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 May 19:13:880262. [Abstract]
JHU-083 (0.3mg/kg; i.v; single) significantly decreases TUNEL-positive cells in mice, which indicates that JHU-083 ameliorates the progression of ConA-induced autoimmune hepatitis by blocking glutamine metabolism in mice.
-
Neuropharmacology
The glutaminase inhibitor JHU-083 mitigates cognitive dysfunction in a mouse model of post-traumatic stress disorder. [Abstract]2025 Nov 15:279:110631. PMID: 40812515 -
bioRxiv
Glutamine antagonism suppresses tumor growth in adrenocortical carcinoma through inhibition of de novo nucleotide biosynthesis. [Abstract]2025 Sep 29:2025.09.28.674326. PMID: 41256360
Solvant et solubilité
DMSO : 100 mg/mL (320.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhu X, et al. JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress. Neuropsychopharmacology. 2019 Mar;44(4):683-694. [Content Brief]
[2]. Riggle BA, et al. MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice. Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E12024-E12033. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2014 mL | 16.0072 mL | 32.0143 mL | 80.0359 mL |
| 5 mM | 0.6403 mL | 3.2014 mL | 6.4029 mL | 16.0072 mL | |
| 10 mM | 0.3201 mL | 1.6007 mL | 3.2014 mL | 8.0036 mL | |
| 15 mM | 0.2134 mL | 1.0671 mL | 2.1343 mL | 5.3357 mL | |
| 20 mM | 0.1601 mL | 0.8004 mL | 1.6007 mL | 4.0018 mL | |
| 25 mM | 0.1281 mL | 0.6403 mL | 1.2806 mL | 3.2014 mL | |
| 30 mM | 0.1067 mL | 0.5336 mL | 1.0671 mL | 2.6679 mL | |
| 40 mM | 0.0800 mL | 0.4002 mL | 0.8004 mL | 2.0009 mL | |
| 50 mM | 0.0640 mL | 0.3201 mL | 0.6403 mL | 1.6007 mL | |
| 60 mM | 0.0534 mL | 0.2668 mL | 0.5336 mL | 1.3339 mL | |
| 80 mM | 0.0400 mL | 0.2001 mL | 0.4002 mL | 1.0004 mL | |
| 100 mM | 0.0320 mL | 0.1601 mL | 0.3201 mL | 0.8004 mL |
JHU-083 Related Classifications
HY-122218 Related Classifications
Powered by Bioz